Actualités

Wall Street is waiting for evidence that AI can change the economics of making drugs. In the lab, AI is already delivering a tangible leap in efficiency, predicting how proteins fold, identifying potential drug targets, and screening millions of molecules virtually. Traditionally, scientists have selected drug targets largely by hand, drawing on the body of research they know best to decide which proteins might matter in a disease, then spending months or years testing those hypotheses in the lab.

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

There are good reasons to invest in Lilly and to hold off.

Eli Lilly plans to present new Alzheimer's research at the 2026 Alzheimer's Association International Conference, including long term data on Kisunla (donanemab-azbt). The company will share updated safety and biomarker findings from its Kisunla program. Eli Lilly will also outline progress on blood based P-tau217 diagnostics that could support broader Alzheimer's screening. Eli Lilly, traded as NYSE:LLY, is set to bring fresh Alzheimer's data to the forefront, while attention has recently...

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.

Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.

Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.

This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.

In the latest monthly list of new buys by the best mutual funds, top money managers aggressively scooped up shares of 19 stocks, including Eli Lilly, GE Aerospace, Taiwan Semiconductor Manufacturing and CrowdStrike.

Biotech is gaining momentum as healthcare leads higher, with several drugmakers and life sciences companies showing improving earnings trends and breakouts.

Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.

Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY) has added over the past year, with shares climbing from $773.86 on July 2, 2025 to $1,213.91 on July 2, 2026, a 56.86% gain that has pushed the drugmaker’s market capitalization to $1.063 trillion. No other Big Pharma name has expanded its footprint ... Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market leaders.

The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker: insurers, device makers, biotech, and Big Pharma. It has returned 21.61% over the past year and 159.84% over ten years. If the reason ... Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA,” ... Jim Cramer Says Biotech is The Hottest Group in The Market Right Now

Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.

AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.

Eli Lilly Wins Positive Canada Recommendation, Strengthening Drug Pipeline

Ebglyss received a positive recommendation that could expand public access.

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lower-cost, easier-to-administer oral pill versions of the current injectable GLP-1s are introduced to the market in 2026, and the field now spans an entrenched leader, a deep-value incumbent, and a clinical-stage challenger with multiple ... 3 High Growth GLP-1 Biotech Winners to Buy in July

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...

In late June 2026, Innovent Biologics announced a distribution and promotion agreement giving it sole commercialization rights for Eli Lilly’s breast cancer drug Verzenios in mainland China, while Lilly retains manufacturing, supply and development responsibilities. At the same time, Eli Lilly received a positive regulatory opinion in Europe for expanding Jaypirca’s use in chronic lymphocytic leukemia, underscoring how partnerships and oncology approvals are broadening the company’s reach...

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.9% and

The chipmaker signaled a major turn in its business, and the market bought it. Now comes the hard part: proving the rally can last.

The stock has soared 400% in recent years.

Check out the companies making headlines yesterday:

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index and the State Street

Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri

The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow process measured in years and billions of dollars, is increasingly becoming a data-driven competition. Companies that combine proprietary medical data with AI tools may gain an advantage similar to what technology companies achieved during the ... Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity